JMP Securities Reaffirms Market Outperform Rating for Enanta Pharmaceuticals (NASDAQ:ENTA)

Enanta Pharmaceuticals (NASDAQ:ENTA)‘s stock had its “market outperform” rating reiterated by research analysts at JMP Securities in a report released on Tuesday,Benzinga reports. They presently have a $21.00 target price on the biotechnology company’s stock. JMP Securities’ target price would indicate a potential upside of 258.36% from the stock’s current price.

Other analysts also recently issued reports about the stock. Robert W. Baird lowered their price target on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating for the company in a research note on Tuesday, November 26th. HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of Enanta Pharmaceuticals in a report on Tuesday. Two investment analysts have rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Enanta Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $17.25.

Enanta Pharmaceuticals Trading Up 4.8 %

ENTA stock opened at $5.86 on Tuesday. The firm has a 50 day moving average of $5.80 and a 200-day moving average of $9.54. Enanta Pharmaceuticals has a 12 month low of $4.71 and a 12 month high of $17.80. The firm has a market capitalization of $124.99 million, a P/E ratio of -1.07 and a beta of 0.54.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.05) EPS for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. Sell-side analysts predict that Enanta Pharmaceuticals will post -5.05 EPS for the current year.

Insider Activity at Enanta Pharmaceuticals

In related news, CEO Jay R. Luly purchased 45,000 shares of the company’s stock in a transaction dated Wednesday, February 12th. The shares were purchased at an average price of $5.69 per share, with a total value of $256,050.00. Following the acquisition, the chief executive officer now directly owns 846,638 shares in the company, valued at $4,817,370.22. The trade was a 5.61 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 13.89% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Krensavage Asset Management LLC boosted its stake in shares of Enanta Pharmaceuticals by 19.7% during the 3rd quarter. Krensavage Asset Management LLC now owns 1,498,074 shares of the biotechnology company’s stock worth $15,520,000 after acquiring an additional 246,736 shares during the last quarter. Geode Capital Management LLC boosted its stake in Enanta Pharmaceuticals by 3.1% during the third quarter. Geode Capital Management LLC now owns 477,351 shares of the biotechnology company’s stock valued at $4,946,000 after buying an additional 14,575 shares during the last quarter. State Street Corp grew its holdings in shares of Enanta Pharmaceuticals by 6.4% in the third quarter. State Street Corp now owns 449,975 shares of the biotechnology company’s stock valued at $4,662,000 after purchasing an additional 27,147 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Enanta Pharmaceuticals by 53.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 243,628 shares of the biotechnology company’s stock worth $2,524,000 after buying an additional 85,082 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its stake in Enanta Pharmaceuticals by 34.1% during the fourth quarter. Assenagon Asset Management S.A. now owns 192,856 shares of the biotechnology company’s stock worth $1,109,000 after acquiring an additional 49,050 shares during the last quarter. Hedge funds and other institutional investors own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.